Deutsche Bank AG lifted its holdings in MacroGenics Inc (NASDAQ:MGNX) by 83.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 221,852 shares of the biopharmaceutical company’s stock after purchasing an additional 100,834 shares during the period. Deutsche Bank AG owned 0.60% of MacroGenics worth $4,213,000 at the end of the most recent reporting period.
Other hedge funds have also added to or reduced their stakes in the company. Cornerstone Capital Management Holdings LLC. lifted its stake in shares of MacroGenics by 43.9% in the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 33,438 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 10,200 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of MacroGenics by 13.6% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 168,988 shares of the biopharmaceutical company’s stock valued at $3,123,000 after purchasing an additional 20,196 shares during the last quarter. OppenheimerFunds Inc. lifted its stake in shares of MacroGenics by 10.8% in the 4th quarter. OppenheimerFunds Inc. now owns 3,933,906 shares of the biopharmaceutical company’s stock valued at $74,744,000 after purchasing an additional 384,861 shares during the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in shares of MacroGenics in the 4th quarter valued at $1,425,000. Finally, Wells Fargo & Company MN lifted its stake in shares of MacroGenics by 11.5% in the 3rd quarter. Wells Fargo & Company MN now owns 27,714 shares of the biopharmaceutical company’s stock valued at $513,000 after purchasing an additional 2,862 shares during the last quarter. 80.03% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts recently issued reports on the stock. Leerink Swann reaffirmed an “outperform” rating on shares of MacroGenics in a research note on Friday, April 6th. Zacks Investment Research lowered shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 6th. BidaskClub lowered shares of MacroGenics from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. Cowen reaffirmed a “buy” rating on shares of MacroGenics in a research note on Wednesday, January 24th. Finally, TheStreet raised shares of MacroGenics from a “d” rating to a “c+” rating in a research note on Tuesday, March 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the stock. MacroGenics currently has a consensus rating of “Buy” and an average target price of $30.25.
MacroGenics stock opened at $24.20 on Tuesday. The firm has a market cap of $993.69, a price-to-earnings ratio of -44.81 and a beta of 2.45. MacroGenics Inc has a fifty-two week low of $14.36 and a fifty-two week high of $32.74.
MacroGenics (NASDAQ:MGNX) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported $2.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.58 by $0.22. The firm had revenue of $152.36 million during the quarter, compared to analyst estimates of $152.59 million. MacroGenics had a negative net margin of 12.44% and a negative return on equity of 8.22%. equities analysts expect that MacroGenics Inc will post -4.42 earnings per share for the current year.
In other MacroGenics news, SVP Eric Blasius Risser sold 1,000 shares of the business’s stock in a transaction on Monday, March 12th. The shares were sold at an average price of $31.08, for a total transaction of $31,080.00. Following the completion of the transaction, the senior vice president now owns 10,100 shares of the company’s stock, valued at approximately $313,908. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Lynn Cilinski sold 23,967 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $25.01, for a total transaction of $599,414.67. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,967 shares of company stock valued at $1,098,005. Company insiders own 8.82% of the company’s stock.
WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/17/deutsche-bank-ag-has-4-21-million-position-in-macrogenics-inc-mgnx.html.
MacroGenics, Inc, a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.